Serum Transaminases in Children with Wilson???s Disease
Authors:
- Raffaele IorioRIRaffaele Iorio
- Mariangela D'AmbrosiMDMariangela D'Ambrosi
- Matilde MarcelliniMMMatilde Marcellini
- Cristiana BarberaCBCristiana Barbera
- Giuseppe MaggioreGMGiuseppe Maggiore
- Lucia ZancanLZLucia Zancan
- Raffaella GiacchinoRGRaffaella Giacchino
- Pietro VajroPVPietro Vajro
- Maria Grazia MarazziMMMaria Grazia Marazzi
- Ruggiero FrancavillaRuggiero Francavilla
- Fabio MichieluttiFMFabio Michielutti
- Massimo RestiMRMassimo Resti
- 1 October 2004
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 39 (4) , 331-336
Abstract
The response of serum transaminase levels to penicillamine and zinc treatment in Wilson's disease is poorly understood. The aim of this multicenter retrospective study was to evaluate transaminase levels after penicillamine and zinc treatment in children with Wilson's disease. One hundred and nine patients with Wilson's disease (median age at diagnosis, 7.2 years; range, 1 to 18 years), treated for at least 12 months and observed in the last 20 years at 11 Paediatric Departments were studied. Clinical, laboratory and histologic features at diagnosis and initial treatment were recorded. Efficacy parameters were normalization of serum transaminase level and improved clinical and/or laboratory signs. One hundred and two patients had clinical or laboratory signs of liver disease. Fifty-six of 87 patients (64%) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Of the 29 patients with persistent hyper-ALT, 17 (59%) switched to zinc; only four of these normalized ALT on zinc within a median period of 38 months (range, 7 to 48 months). Eleven (50%) of the 22 patients given zinc alone normalized ALT within a median period of 6 months (range, 1 to 36 months). Of the 11 patients with persistent hyper-ALT, five switched to penicillamine. Three of the five normalized ALT within a median period of 6 months (range, 6 to 9 months). Overall, in penicillamine-treated and zinc-treated patients with persistent hypertransaminasemia, ALT decreased from a basal median of 236 IU/L (range, 54 to 640 IU/L) to a median of 78 (range, 46 to 960 IU/L) at the end of follow-up (P = 0.0245). Poor compliance was suspected in only 10% of cases. No predictive factor of persistent hypertransaminasemia was identified. Liver disease did not worsen in any patient during the study. Although the efficacy of penicillamine and zinc is well documented, it is notable that a subset of children with Wilson's disease-related liver disease (36%) had hypertransaminasemia despite appropriate treatment with penicillamine or zinc.Keywords
This publication has 29 references indexed in Scilit:
- A Practice Guideline on Wilson DiseaseHepatology, 2003
- Treatment of Wilson's disease with zinc XVI: Treatment during the pediatric yearsJournal of Laboratory and Clinical Medicine, 2001
- A High Index of Suspicion: The Key to an Early Diagnosis of Wilson's Disease in ChildhoodJournal of Pediatric Gastroenterology and Nutrition, 1999
- The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease geneNature Genetics, 1993
- Wilson's disease: Current statusThe American Journal of Medicine, 1992
- Perspectives on Wilson's diseaseHepatology, 1990
- DANGERS OF NON-COMPLIANCE IN WILSON'S DISEASEThe Lancet, 1986
- TREATMENT OF WILSON'S DISEASE WITH TRIENTINE (TRIETHYLENE TETRAMINE) DIHYDROCHLORIDEThe Lancet, 1982
- WILSONʼS DISEASEMedicine, 1975
- Penicillamine, a new oral therapy for Wilson's diseaseThe American Journal of Medicine, 1956